Drug Profile
Research programme: therapeutic antibodies - Zebra Biologics
Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Zebra Biologics
- Developer AbbVie; Zebra Biologics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Diabetes mellitus; Inflammation; Neurological disorders; Obesity
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Inflammation in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)